American news outlets are FINALLY reporting that Wuhan virus MAY HAVE come from a LAB! – Investment Watch investmentwatchblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investmentwatchblog.com Daily Mail and Mail on Sunday newspapers.
Coronavirus update: Another new treatment drug, investigating the virus’ origin
Fewer people are filing unemployment claims 05/27/2021
Total U.S. confirmed cases: 33,192,974 (33,171,024)
Total U.S. deaths: 592,432 (591,116)
Total global cases: 168,520,476 (167,961,302)
Total global deaths: 3,500,945 (3,488,454)
FDA gives emergency approval to new treatment drug
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to a new coronavirus treatment drug made by GlaxoSmithKline and Vir Biotechnology. The monoclonal antibody drug has been shown to be effective in treating early COVID-19 infections.
The drug, called sotrovimab, is the third antibody product that the FDA has authorized to treat patients in the early stages of the disease but who may be vulnerable to a severe case.
Sotrovimab will be available for appropriate patients diagnosed with COVID-19 in the US in the coming weeks and discussions with global regulators regarding authorisations in additional countries continue to advance, said GSK
SCIENCE; (DATA) OUR WORLD IN DATA
All told, 14 billion doses could leave factories before the year is over, according to a document written in advance of a March summit about stepping up the production pace. That s a startling number before the pandemic, all of the world s vaccinemakers together produced at most 5.5 billion doses annually and the document stresses that it s the best of all scenarios. “We have a set of manufacturing challenges that make it unlikely that we can meet the 14-billion aspiration,” cautions Lurie, who helped organize the meeting.
Raw materials, such as disposable bags that line bioreactors, filters, and cell-culture media, are the biggest challenge. “Raw material inputs have nowhere near kept up with the anticipated demand,” Lurie says. Importing and exporting delays have exacerbated the shortages, and travel bans have made it difficult to move experts around the world to troubleshoot manufacturing snafus. Almost every vaccine producer has failed